You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTemazepam
Accession NumberDB00231  (APRD00676)
TypeSmall Molecule
GroupsApproved
Description

A benzodiazepine that acts as a gamma-aminobutyric acid modulator and anti-anxiety agent. [PubChem]

Structure
Thumb
Synonyms
Restoril
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Co Temazepam Capsules 15mgcapsule15 mgoralCobalt Pharmaceuticals Company2002-08-142015-08-07Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Co Temazepam Capsules 30mgcapsule30 mgoralCobalt Pharmaceuticals Company2002-08-142015-08-07Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-temazepamcapsule30 mgoralDominion Pharmacal1997-03-16Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-temazepamcapsule15 mgoralDominion Pharmacal1996-12-16Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Gen-temazepam 15mgcapsule15 mgoralGenpharm Ulc1997-07-082009-10-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Gen-temazepam 30mgcapsule30 mgoralGenpharm Ulc1997-07-082009-10-15Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ntp-temazepamcapsule15 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ntp-temazepamcapsule30 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-temazepamcapsule30 mgoralNu Pharm Inc1996-08-162012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-temazepamcapsule15 mgoralNu Pharm Inc1996-08-162012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Penta-temazepam Capsulescapsule30 mgoralPentapharm Ltd.Not applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Penta-temazepam Capsulescapsule15 mgoralPentapharm Ltd.Not applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-temazepamcapsule15 mgoralPharmel Inc2007-07-27Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-temazepamcapsule30 mgoralPharmel Inc2007-07-27Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-temazepamcapsule30 mgoralPharmascience Inc2005-11-29Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-temazepamcapsule15 mgoralPharmascience Inc2005-11-29Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-temazepam - 15mgcapsule15 mgoralPharmascience Inc1996-10-172009-10-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-temazepam - 30mgcapsule30 mgoralPharmascience Inc1996-10-172009-10-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-temazepamcapsule30 mgoralRatiopharm Inc Division Of Teva Canada Limited2001-02-192014-09-19Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-temazepamcapsule15 mgoralRatiopharm Inc Division Of Teva Canada Limited2001-02-192014-09-19Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Restorilcapsule7.5 mg/1oralCardinal Health2008-11-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Restorilcapsule30 mgoralAspri Pharma Canada Inc1980-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Restorilcapsule15 mgoralAspri Pharma Canada Inc1980-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Restorilcapsule30 mg/1oralMallinckrodt, Inc.2011-07-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Restorilcapsule15 mg/1oralMallinckrodt, Inc.2011-07-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Restorilcapsule7.5 mg/1oralMallinckrodt, Inc.2011-07-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Restorilcapsule22.5 mg/1oralMallinckrodt, Inc.2011-07-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralKAISER FOUNDATION HOSPITALS2010-03-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralMallinckrodt, Inc.2010-02-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule22.5 mg/1oralMallinckrodt, Inc.2010-02-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralAmerican Health Packaging2012-02-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepam-15capsule15 mgoralPro Doc Limitee1997-08-06Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Temazepam-30capsule30 mgoralPro Doc Limitee1997-08-06Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-temazepamcapsule30 mgoralTeva Canada Limited1996-12-18Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-temazepamcapsule15 mgoralTeva Canada Limited1996-12-18Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-temazepamcapsule30 mgoralApotex Inc1996-10-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-temazepamcapsule15 mgoralApotex Inc1996-10-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Temazepamcapsule15 mg/1oralRebel Distributors Corp1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralPhysicians Total Care, Inc.2005-01-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralA S Medication Solutions Llc1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralProficient Rx LP1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralKAISER FOUNDATION HOSPITALS2003-06-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralPd Rx Pharmaceuticals, Inc.1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralREMEDYREPACK INC.2014-03-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralAphena Pharma Solutions Tennessee, Llc1988-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralQualitest Pharmaceuticals2015-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralNovel Laboratories, Inc.2009-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralAscend Laboratories, LLC1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralSandoz Inc1988-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-08-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralA S Medication Solutions Llc1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralTYA Pharmaceuticals1988-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralMylan Pharmaceuticals Inc.1986-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralNovel Laboratories, Inc.2012-06-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralCardinal Health2012-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralREMEDYREPACK INC.2013-03-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralAscend Laboratories, LLC1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralSandoz Inc1988-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralDIRECT RX2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralMutual Pharmaceutical Company, Inc.2006-10-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-09-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralMylan Pharmaceuticals Inc.1986-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule22.5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-06-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralCardinal Health2012-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralMylan Institutional Inc.1997-05-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralAphena Pharma Solutions Tennessee, Llc1988-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralSTAT Rx USA LLC2010-05-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralDIRECT RX2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule22.5 mg/1oralMutual Pharmaceutical Company, Inc.2006-10-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralMc Kesson Contract Packaging2011-11-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralMc Kesson Packaging Services1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule22.5 mg/1oralMylan Pharmaceuticals Inc.2009-06-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralLake Erie Medical DBA Quality Care Products LLC1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralCardinal Health2011-02-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralMylan Institutional Inc.1997-04-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralSTAT Rx USA LLC2010-05-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralMutual Pharmaceutical Company, Inc.2006-10-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralAphena Pharma Solutions Tennessee, Llc1987-08-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralMylan Pharmaceuticals Inc.2010-05-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralLake Erie Medical DBA Quality Care Products LLC1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralCardinal Health2011-02-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule22.5 mg/1oralUnit Dose Services2012-06-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralMc Kesson Contract Packaging2011-12-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralMc Kesson Packaging Services1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralQualitest Pharmaceuticals2015-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralAv Kare, Inc.2015-08-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralGolden State Medical Supply, Inc.2014-01-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralMutual Pharmaceutical Company, Inc.2009-09-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralActavis Elizabeth LLC1995-01-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralRx Change Co.2014-11-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralCardinal Health1988-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralUnit Dose Services1987-08-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralPreferred Pharmaceuticals, Inc2012-02-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralbryant ranch prepack1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralNovel Laboratories, Inc.2009-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralGolden State Medical Supply, Inc.2014-01-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralH.J. Harkins Company, Inc.1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralAphena Pharma Solutions Tennessee, Llc1987-08-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule22.5 mg/1oralQualitest Pharmaceuticals2015-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralProficient Rx LP1986-07-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralPhysicians Total Care, Inc.2008-01-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule22.5 mg/1oralAscend Laboratories, LLC2012-06-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralSTAT Rx USA LLC1987-08-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralA S Medication Solutions Llc1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralRebel Distributors Corp1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralCardinal Health1988-01-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralUnit Dose Services1987-08-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralPreferred Pharmaceuticals, Inc2012-02-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralbryant ranch prepack1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralActavis Elizabeth LLC1995-01-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralPd Rx Pharmaceuticals, Inc.1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralH.J. Harkins Company, Inc.1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-10-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralQualitest Pharmaceuticals2015-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule22.5 mg/1oralNovel Laboratories, Inc.2012-06-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule15 mg/1oralProficient Rx LP1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralA S Medication Solutions Llc1987-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralAscend Laboratories, LLC2012-06-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule7.5 mg/1oralMajor Pharmaceuticals2015-03-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Temazepamcapsule30 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
EuhypnosNot Available
NorkotralNot Available
NormisonNot Available
NortemNot Available
RemestanNot Available
TemazeNot Available
TemtabsNot Available
Brand mixtures
NameLabellerIngredients
StrazepamPhysician Therapeutics Llc
SaltsNot Available
Categories
CAS number846-50-4
WeightAverage: 300.74
Monoisotopic: 300.066555377
Chemical FormulaC16H13ClN2O2
InChI KeyInChIKey=SEQDDYPDSLOBDC-UHFFFAOYSA-N
InChI
InChI=1S/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3
IUPAC Name
7-chloro-3-hydroxy-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the short-term treatment of insomnia (generally 7-10 days).
PharmacodynamicsTemazepam is a benzodiazepine used as a hypnotic agent in the management of insomnia. Temazepam produces CNS depression at limbic, thalamic, and hypothalamic levels of the CNS. Temazepam increases the affinity of the neurotransmitter gamma-aminobutyric acid (GABA) for GABA receptors by binding to benzodiazepine receptors. Results are sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action.
Mechanism of actionBenzodiazepines bind nonspecifically to benzodiazepine receptors, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
AbsorptionWell absorbed, minimal first-pass metabolism.
Volume of distributionNot Available
Protein binding96%
Metabolism

Hepatic. Temazepam is completely metabolized through conjugation prior to excretion. The major metabolite is the O-conjugate of temazepam (90%).

SubstrateEnzymesProduct
Temazepam
OxazepamDetails
Temazepam
Not Available
Oxazepam glucuronideDetails
Route of eliminationTemazepam was completely metabolized through conjugation prior to excretion; 80% to 90% of the dose appeared in the urine.
Half life10-20 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9913
Blood Brain Barrier+0.9745
Caco-2 permeable+0.7979
P-glycoprotein substrateNon-substrate0.55
P-glycoprotein inhibitor INon-inhibitor0.7388
P-glycoprotein inhibitor IIInhibitor0.546
Renal organic cation transporterNon-inhibitor0.7776
CYP450 2C9 substrateNon-substrate0.6281
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6962
CYP450 1A2 substrateInhibitor0.5916
CYP450 2C9 inhibitorNon-inhibitor0.5454
CYP450 2D6 inhibitorNon-inhibitor0.891
CYP450 2C19 inhibitorNon-inhibitor0.5615
CYP450 3A4 inhibitorNon-inhibitor0.6014
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6494
Ames testNon AMES toxic0.7974
CarcinogenicityNon-carcinogens0.8093
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0888 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9987
hERG inhibition (predictor II)Non-inhibitor0.8308
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Tyco healthcare group lp
  • Quantum pharmics ltd
  • Actavis elizabeth llc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Novel laboratories inc
  • Sandoz inc
  • Usl pharma inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral15 mg
Capsuleoral30 mg
Kit
Capsuleoral15 mg/1
Capsuleoral22.5 mg/1
Capsuleoral30 mg/1
Capsuleoral7.5 mg/1
Prices
Unit descriptionCostUnit
Restoril 22.5 mg capsule11.37USD capsule
Restoril 7.5 mg capsule11.37USD capsule
Temazepam 22.5 mg capsule9.94USD capsule
Temazepam 7.5 mg capsule9.94USD capsule
Restoril 15 mg capsule7.87USD capsule
Restoril 30 mg capsule7.67USD capsule
Temazepam 30 mg capsule0.69USD capsule
Temazepam 15 mg capsule0.58USD capsule
Apo-Temazepam 30 mg Capsule0.14USD capsule
Co Temazepam 30 mg Capsule0.14USD capsule
Novo-Temazepam 30 mg Capsule0.14USD capsule
Pms-Temazepam 30 mg Capsule0.14USD capsule
Ratio-Temazepam 30 mg Capsule0.14USD capsule
Apo-Temazepam 15 mg Capsule0.12USD capsule
Co Temazepam 15 mg Capsule0.12USD capsule
Novo-Temazepam 15 mg Capsule0.12USD capsule
Pms-Temazepam 15 mg Capsule0.12USD capsule
Ratio-Temazepam 15 mg Capsule0.12USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States52119541993-05-182010-05-18
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point119-121 °CPhysProp
water solubility164 mg/LNot Available
logP2.19HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0534 mg/mLALOGPS
logP2.16ALOGPS
logP2.79ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)10.68ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.9 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity81.01 m3·mol-1ChemAxon
Polarizability30.32 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-ifz5000000-eba55d0cdbd09c877424View in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. Pubmed
  2. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. Pubmed
  3. Vozeh S: [Pharmacokinetic of benzodiazepines in old age] Schweiz Med Wochenschr. 1981 Nov 21;111(47):1789-93. Pubmed
  4. Shats V, Kozacov S: [Falls in the geriatric department: responsibility of the care-giver and the hospital] Harefuah. 1995 Jun 1;128(11):690-3, 743. Pubmed
  5. Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. Pubmed
External Links
ATC CodesN05CD07
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AminophyllineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Aminophylline.
AzelastineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Temazepam.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
BuprenorphineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
ClozapineThe risk or severity of adverse effects can be increased when Temazepam is combined with Clozapine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
DyphyllineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Dyphylline.
EthanolTemazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Temazepam.
Gamma Hydroxybutyric AcidTemazepam may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.
HydrocodoneTemazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Temazepam.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
MethadoneTemazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethotrimeprazineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MetyrosineTemazepam may increase the sedative activities of Metyrosine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
MirtazapineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Temazepam.
OrphenadrineTemazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ParaldehydeTemazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Temazepam is combined with Paroxetine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Temazepam.
PramipexoleTemazepam may increase the sedative activities of Pramipexole.
RopiniroleTemazepam may increase the sedative activities of Ropinirole.
RotigotineTemazepam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Temazepam.
Sodium oxybateTemazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
SuvorexantTemazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Temazepam.
TeduglutideThe serum concentration of Temazepam can be increased when it is combined with Teduglutide.
ThalidomideTemazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TheophyllineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Theophylline.
YohimbineThe therapeutic efficacy of Temazepam can be decreased when used in combination with Yohimbine.
ZolpidemTemazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Avoid alcohol.
  • Avoid avocado.
  • Avoid excessive quantities of coffee or tea (Caffeine).

Targets

1. Gamma-aminobutyric acid receptor subunit alpha-1

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-1 P14867 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

2. Gamma-aminobutyric acid receptor subunit alpha-2

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-2 P47869 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

3. Gamma-aminobutyric acid receptor subunit alpha-3

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-3 P34903 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

4. Gamma-aminobutyric acid receptor subunit alpha-4

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-4 P48169 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

5. Gamma-aminobutyric acid receptor subunit alpha-5

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-5 P31644 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

6. Gamma-aminobutyric acid receptor subunit alpha-6

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-6 Q16445 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

7. Gamma-aminobutyric acid receptor subunit beta-1

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit beta-1 P18505 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

8. Gamma-aminobutyric acid receptor subunit beta-2

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit beta-2 P47870 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

9. Gamma-aminobutyric acid receptor subunit beta-3

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit beta-3 P28472 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

10. Gamma-aminobutyric acid receptor subunit gamma-1

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit gamma-1 Q8N1C3 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

11. Gamma-aminobutyric acid receptor subunit gamma-2

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit gamma-2 P18507 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

12. Gamma-aminobutyric acid receptor subunit gamma-3

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit gamma-3 Q99928 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

13. Gamma-aminobutyric acid receptor subunit delta

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit delta O14764 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

14. Gamma-aminobutyric acid receptor subunit epsilon

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit epsilon P78334 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

15. Gamma-aminobutyric acid receptor subunit pi

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit pi O00591 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

16. Gamma-aminobutyric acid receptor subunit rho-1

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit rho-1 P24046 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

17. Gamma-aminobutyric acid receptor subunit rho-2

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit rho-2 P28476 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

18. Gamma-aminobutyric acid receptor subunit rho-3

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit rho-3 A8MPY1 Details

References:

  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. Pubmed
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed

19. Gamma-aminobutyric acid receptor subunit theta

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: potentiator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit theta Q9UN88 Details

References:

  1. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. Pubmed
  2. Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. Pubmed

20. Translocator protein

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: other

Components

Name UniProt ID Details
Translocator protein P30536 Details

References:

  1. Dobbin M, Martyres RF, Clode D, Champion De Crespigny FE: Association of benzodiazepine injection with the prescription of temazepam capsules. Drug Alcohol Rev. 2003 Jun;22(2):153-7. Pubmed
  2. Miller EI, Wylie FM, Oliver JS: Detection of benzodiazepines in hair using ELISA and LC-ESI-MS-MS. J Anal Toxicol. 2006 Sep;30(7):441-8. Pubmed
  3. Mant A, Whicker SD, McManus P, Birkett DJ, Edmonds D, Dumbrell D: Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database. Aust J Public Health. 1993 Dec;17(4):345-9. Pubmed

21. GABA-A receptor (anion channel)

Kind: Protein group

Organism: Human

Pharmacological action: yes

Actions: positive allosteric modulator

Components

Name UniProt ID Details
Gamma-aminobutyric acid receptor subunit alpha-1 P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2 P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3 P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4 P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5 P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6 Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1 P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2 P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3 P28472 Details
Gamma-aminobutyric acid receptor subunit delta O14764 Details
Gamma-aminobutyric acid receptor subunit epsilon P78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1 Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2 P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3 Q99928 Details
Gamma-aminobutyric acid receptor subunit pi O00591 Details
Gamma-aminobutyric acid receptor subunit theta Q9UN88 Details

References:

  1. ChEMBL Compound Report Card (Accessed December 2013)

Enzymes

1. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Application available online: The P450 Program
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Shou M, Mei Q, Ettore MW Jr, Dai R, Baillie TA, Rushmore TH: Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J. 1999 Jun 15;340 ( Pt 3):845-53. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 2B6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2B6 P20813 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 2C8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2013 14:46